The committee will discuss new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant’s proposed indication is treatment of hospital‐acquired bacterial pneumonia (HABP) and ventilator‐associated bacterial pneumonia (VABP) caused by susceptible strains of Acinetobacter baumannii‐calcoaceticus complex (ABC) in adults.
Link to Meeting Information and Materials: [ Ссылка ]

свернуть